DIVENSTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			36 Months Ended	84 Months Ended
	Feb. 28, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2026	Dec. 31, 2023	Dec. 31, 2022
Licensing Arrangements [Line Items]
Payment to extinguish future royalty obligation			$ 295
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Proceeds from legal settlements		$ 400		$ 40
Contingent sales-based milestones	$ 2,000
Other (income)/expense		$ 400
Keytruda Royalties | Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner						6.50%
Keytruda Royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner					2.50%
Immatics
Licensing Arrangements [Line Items]
Upfront payments				150
Contingent and regulatory milestone payments				770
Dragonfly
Licensing Arrangements [Line Items]
Upfront payments				$ 175
Nimbus Therapeutics
Licensing Arrangements [Line Items]
Upfront payments	$ 4,000
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Change in control proceeds				10.00%
Percentage of ownership acquired	100.00%
Bristol-Myers Squibb | Keytruda Royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Payment and royalty allocation					75.00%
Ono | Keytruda Royalties | Forecast | Subsequent Event
Licensing Arrangements [Line Items]
Payment and royalty allocation					25.00%
Mature products and other | Discontinued Operations, Held-for-sale
Licensing Arrangements [Line Items]
Assets held for sale							$ 172
Liabilities held for sale							20
Mature products and other | Cost of products sold
Licensing Arrangements [Line Items]
Asset impairment charges			$ 63
Mature products and other | LOTTE Corporation
Licensing Arrangements [Line Items]
Sales price							$ 159